drugset / Trial / NCT04931563
Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).
Timeline
- Start
- 2021-09-13
- Primary completion
- 2025-04-07
- Completion
- 2025-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Anifrolumab | Monoclonal antibody | 300 mg | Intravenous |